BioTime, Inc. Announces Closing of Public Offering and Underwriters’ Full Exercise of Over-Allotment Option
ALAMEDA, Calif.–(BUSINESS WIRE)–Oct. 17, 2017– BioTime, Inc. (“BioTime”) (NYSE American and TASE: BTX), a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced the closing of its previously announced public offering of 9,615,385 shares of common stock, including 1,442,308 shares sold pursuant to the underwriters’ exercise in full of their... Read more